Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4126243 | 0.94 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL4120223 | 0.94 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL4119132 | 0.93 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL4127225 | 0.90 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL16569484 | 0.87 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL4120876 | 0.84 | SMYD2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL4125337 | 0.82 | ABL1 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL22070652 | 0.82 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL16837066 | 0.81 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL27039618 | 0.81 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735451-A1 | SUBSTITUTED CONDENSED TRICYCLIC AMINE COMPOUNDS AND USES THEREOF AS RAS INHIBITORS | Kumquat Biosciences Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260028358-A1 | SUBSTITUTED HETEROAROMATIC AMINES AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2026-01-29 | — | — | US | disclosed |
| WO-2025007000-A1 | SUBSTITUTED CONDENSED TRICYCLIC AMINE COMPOUNDS AND USES THEREOF AS RAS INHIBITORS | KUMQUAT BIOSCIENCES INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| EP-3356344-B1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LTD (GB) | 2022-11-16 | — | — | EP | disclosed |
| CN-108473464-B | Isoindolinone inhibitors of MDM2-P53 interaction with anti-cancer activity | 阿斯泰克斯治疗有限公司 | 2022-08-23 | — | — | CN | disclosed |
| US-20220106287-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2022-04-07 | — | — | US | disclosed |
| US-11261171-B1 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (GB) | 2022-03-01 | — | — | US | disclosed |
| EP-3221300-B1 | ANTIBACTERIAL BENZOTHIAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-03-20 | — | — | EP | disclosed |
| US-20190055215-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2019-02-21 | — | — | US | disclosed |
| US-20190031676-A1 | ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-01-31 | — | — | US | disclosed |
| EP-2379548-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA A/S (DK) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010069322-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA A/S (DK) | 2010-06-24 | — | — | WO | disclosed |
| US-20100113442-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | FELDING JAKOB | 2010-05-06 | — | — | US | disclosed |
| US-20100113442-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | FELDING JAKOB | 2010-05-06 | — | — | US | disclosed |
| EP-2146989-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | Leo Pharma A/S (DK) | 2010-01-27 | — | — | EP | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
| WO-2008125111-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA A/S (DK) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106287-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | SMYD2 3947/4885CYP3A4 1227/4885HTT 352/4885 |
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | SMYD2 3091/4885CYP3A4 157/4885HTT 3905/4885 |
| US-20260028358-A1 | SUBSTITUTED HETEROAROMATIC AMINES AND USES THEREOF | HRAS, KRAS, BCL6 | SMYD2 3619/4885CYP3A4 3608/4885HTT 1996/4885 |
| US-20190055215-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | SMYD2 3947/4885CYP3A4 1227/4885HTT 352/4885 |
| US-20190031676-A1 | ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES | PYCR1, PSPH, RPSA | SMYD2 49/4885CYP3A4 3357/4885HTT 4041/4885 |
| US-20100113442-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | PDE5A, PDE3A, PDE3B | SMYD2 1738/4885CYP3A4 836/4885HTT 2418/4885 |
| US-11261171-B1 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | TP53, MDM2, TP53BP1 | SMYD2 3947/4885CYP3A4 1227/4885HTT 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.